SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers

E. Cordova1, B. Bacelar1, F. Nieto1, F. Garibaldi1, V. Aguirre3, M. Machuca1, M. Badia3 and C. Rodriguez1

1Infectious Diseases Unit, Hospital Cosme Argerich, Buenos Aires, C1155 AHD, Argentina, 2Central Laboratory, Hospital Cosme Argerich, Buenos Aires, Argentina, 3Health Promotion and Protection Unit, Hospital Cosme Argerich, Buenos Aires, C1155 AHD, Argentina.

Correspondence to: E. Cordova, Infectious Diseases Unit, Hospital Cosme Argerich, Pi y Margall 750, Buenos Aires, C1155 AHD, Argentina. Tel: 54 911 61835390; fax: 54 11 43075952; e-mail: dr_ecordova@hotmail.com

Background
Healthcare workers (HCWs) accounted for a significant proportion of COVID-19 infections worldwide. Retrospective seroprevalence surveys are often used to screen for unidentified previous infection with SARS-CoV-2. However, the rate of humoral response in HCWs affected by COVID-19 is not well-defined.

Aims
To assess the specific IgG humoral response in symptomatic and asymptomatic SARS-CoV-2-infected HCWs and identify potential factors associated with humoral response.

Methods
We prospectively recruited 204 HCWs with RT-PCR-confirmed COVID-19 infection to evaluate SARS-CoV-2 humoral response. Serum-IgG antibodies against SARS-CoV-2 were analysed using two commercially available serological assays. A logistic regression was performed to identify independent factors associated with positive IgG serology test.

Results
Overall, the SARS-CoV-2 IgG seropositivity rate was 77%. This seropositivity rate was higher in symptomatic than in asymptomatic COVID-19 infection (83% versus 57%; \( P < 0.001 \)) and in older HCWs. The seropositivity rate did not diminish with time. In logistic regression, only a history of COVID-19 symptoms and age were identified as independent factors associated with the detection of anti-SARS-CoV-2 IgG antibodies.

Conclusions
SARS-CoV-2 IgG antibodies are found significantly more frequently in symptomatic and in older HCWs. The fact that not all COVID-19 HCWs develop detectable IgG is vital for the interpretation of COVID-19 seroprevalence surveys.

Key words
COVID-19; healthcare workers; infection; occupational medicine; SARS-CoV-2; serology.

Introduction
Healthcare workers (HCWs) have an increased risk of acquiring SARS-CoV-2 infection in comparison with other individuals in the community. HCWs represent a significant proportion of COVID-19 infections worldwide, with >570 000 infections and 2500 deaths reported up to September 2020 [1].

Retrospective seroprevalence surveys are usually used to screen for unidentified previous SARS-CoV-2 infection [2]. However, the rate of humoral response in HCWs affected by COVID-19 is not well-defined, especially in those who are asymptomatic or have mild symptoms. For that reason, these seroprevalence surveys are difficult to interpret and probably underestimate the real rate of SARS-CoV-2 infection in this high-exposure population.

This study aimed to assess the specific IgG humoral response in SARS-CoV-2-infected HCWs and identify potential factors associated with humoral response.

Methods
We prospectively recruited volunteer HCWs with previous RT-PCR-confirmed COVID-19 infection to evaluate SARS-CoV-2 IgG humoral response between 13 August and 26 November 2020, at the Hospital Cosme Argerich, Buenos Aires, Argentina.
A self-administered questionnaire was used to capture epidemiological, and clinical information. Two commercial qualitative immunoassays were used: the COVIDAR Argentina Consortium enzyme-linked immunosorbent assay (ELISA) test (Laboratorio Lemos, Argentina), which measures IgG against spike (S)-protein and the Architect chemiluminescent microparticle immunoassay (CMIA) (Abbott Laboratories, USA), which measures IgG against nucleocapsid (N)-protein. Serologic response was defined as at least one of the assays being positive.

Statistical analyses were performed using Epi Info software version 7.2. Categorical variables were described using absolute and relative frequencies and compared by the Fisher exact test. Continuous variables were described using medians with interquartile ranges (IQRs) and compared by the Anova test for differences between groups. All tests were considered significant if P-value was <0.05. A logistic regression was undertaken to identify independent factors associated with positive IgG serology test.

The protocol was approved by the Hospital Cosme Argerich Bioethics Committee. HCWs were included after a written informed consent.

Results

A total of 204 HCWs after COVID-19 infection were included. Clinical and epidemiological characteristics are shown in Table 1. The median time between SARS-CoV-2 diagnosis and serological test sample was 57 days (IQR 41–75); up to 8 weeks 56% and >8 weeks, 44% of the cases.

Overall SARS-CoV-2 IgG seropositivity rate was 77%. Anti-S and anti-N IgG seropositivity rate was 73% and 69%, respectively. Seropositivity rate was higher in symptomatic than in asymptomatic COVID-19 infection (83% versus 57%; P < 0.001). Similarly, seropositivity rate was higher in HCWs with severe COVID-19 than those with mild/moderate COVID, but this difference was not significant (96% versus 81%; P = NS). Differences in signal-to-cut-off (S/CO)

| Table 1. Clinical and epidemiological characteristics of 204 COVID-19 convalescent HCWs |
|--------------------------------------|-----------|
| Characteristics                      | n (%)     |
| Age: median (IQR)                    | 41.5 (34–52) |
| Gender: male/female                  | 61 (30)/143 |
| Hospital activity                    | 77 (38)   |
| Nurses                               | 42 (21)   |
| Physicians                           | 85 (42)   |
| Most probable source of infection for SARS-CoV-2 |
| Unknown                              | 128 (63)  |
| Nosocomial close contact with COVID-19|
| patient                              | 51 (25)   |
| Household transmission               | 25 (12)   |
| Staff with direct contact to COVID-19|
| patients                             | 140 (69)  |
| Any co-morbidity                     | 41 (20)   |
| Asymptomatic COVID-19                | 44 (22)   |
| Mild/moderate COVID-19                | 137 (67)  |
| Severe COVID-19                      | 23 (11)   |

Data are numbers (percentages) unless stated otherwise.
ratio were observed according to the severity of the disease. Median S/CO in asymptomatic, mild, moderate and severe cases were 4.7, 6.0 and 9.9 ($P < 0.05$) for anti-S IgG; and 4.4, 4.8 and 6.3 ($P < 0.05$) for anti-N IgG, respectively.

Age was associated with increased seropositivity rate. The median age of HCWs with positive IgG serology was 43 versus 37 years for those with negative serology ($P < 0.01$).

No significant differences were observed in the overall seropositivity rate according to the time elapsed from the infection to the collection of serum samples (80% ≤ 8 weeks versus 74% > 8 weeks; $P = NS$). The same was observed in asymptomatic (54% versus 61%; $P = NS$) and symptomatic (87% versus 78%; $P = NS$) HCWs. In logistic regression, only a history of COVID-19 symptoms and age were identified as independent factors associated with detectable SARS-CoV-2 IgG antibodies (Table 2).

**Discussion**

In this group of HCWs with previous confirmed COVID-19 infection, not all had a positive SARS-CoV-2 IgG serology assay. Increased likelihood of a positive serology was observed in those HCWs with COVID-19 symptoms at the time of the infection and with increased aged. Interestingly, only about half of the asymptomatic HCWs had a positive serology. This observation is similar to previous studies [3,4]. In those studies, IgG humoral response as well as antibodies titres were lower in asymptomatic patients in comparison with those who had COVID-19-associated symptoms.

The duration of IgG humoral response is not yet well-established. Initially, some studies reported a rapid decay within weeks of antibody titres after SARS-CoV-2 infection [4,5]. In our study, seropositivity rate was independent of the time elapsed from infection to serum sampling, even in those with or without history of COVID-19 symptoms. Furthermore, the seropositivity rate in samples obtained after 8 weeks did not differ significantly from those with a shorter time interval. In addition, a prolonged persistence of IgG humoral response was recently described with a median time of antibody detection of >150 days [6,7].

Age was also associated as an independent risk factor for a positive IgG serology test. A possible explanation for this observation would be an increased mucosal antibody response and a more effective local control in younger SARS-CoV-2-exposed individuals [8]. Similarly, increasing age was recently associated with higher antibody levels and a longer duration of seropositivity [7].

Commercial SARS-CoV-2 immunoassays do not differentiate protective neutralizing antibodies from non-neutralizing or binding antibodies. Thus, the detection of antibodies is not useful to stop taking measures to protect against SARS-CoV-2 infection [9]. However, a recent published study reported that the detection of anti-S or anti-N IgG antibodies was associated with a significant lower risk of SARS-CoV-2 reinfection among HCWs up to 6 months of follow-up [10].

This study has some limitations. Subjects were enrolled in a voluntary and flexible schedule. Therefore, the time point of serum sampling was variable. Moreover, since serology was not performed prospectively, we could not study individual response kinetics.

In summary, we found that detectable SARS-CoV-2 IgG antibodies are significantly more frequent in symptomatic and in older HCWs. The fact that not all COVID-19 HCWs have a positive serology is vital for the interpretation of seroprevalence surveys. These results now highlight the importance of screening for the detection of anti-SARS-CoV-2 antibodies in HCWs, especially in settings where there is a limited vaccine availability.

**Funding**

The authors received no financial support for the research, authorship and/or publication of this article.

**Acknowledgements**

We would like to thank the members of Phonoaudiology Service, and Dra. Silvina Bernasconi and Dra. Andrea Zappi for their selfless collaboration in the study.

**Competing interests**

None declared.

| Table 2. Univariate and multivariable analysis of characteristics associated with a positive serology in HCWs after confirmed COVID-19 infection |
|--------------------------------------------------|------------------|-----------------|-----------------|-----------------|
| Variables                          | Unadjusted OR (95% CI), n = 204 | P-value | Adjusted OR (95% CI), n = 204 | P-value |
| Male sex                           | 1.71 (0.79–3.72) | 0.17 | 1.03 (1.01–1.07) | 0.03 |
| Age                                | 1.04 (1.01–1.08) | 0.008 | 3.10 (1.47–6.54) | 0.002 |
| Any co-morbidity                   | 1.25 (0.53–2.94) | 0.60 | 4.17 (0.53–32.94) | 0.17 |
| COVID-19 symptoms                  | 3.74 (1.81–7.74) | 0.004 | 3.10 (1.47–6.54) | 0.002 |
| Severe COVID-19                    | 7.38 (0.97–56.36) | 0.05 | 4.17 (0.53–32.94) | 0.17 |
References

1. Erdem H, Lucey DR. Healthcare worker infections and deaths due to COVID-19: a survey from 37 nations and a call for WHO to post national data on their website. *Int J Infect Dis* 2021;102:239–241.

2. Chou R, Dana T, Buckley DJ, Selph S, Fu R, Totten AM. Update alert 5: epidemiology of and risk factors for coronavirus infection in health care workers. *Ann Intern Med* 2020;173:W155.

3. Wellinghausen N, Plonné D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. *J Clin Virol* 2020;130:104542.

4. Long QX, Tang XJ, Shi QL et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020;26:1200–1204.

5. Seow J, Graham C, Merrick B et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* 2020;5:1598–1607.

6. Duysburgh E, Mortgat L, Barbezange C et al. Persistence of IgG response to SARS-CoV-2. *Lancet Infect Dis* 2021;21:163–164. doi:10.1016/S1473-3099(20)30943-9.

7. Lumley SF, Wei J, O’Donnell D et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. *Clin Infect Dis* 2021:ciab004. doi:10.1093/cid/ciab004.

8. Cervia C, Nilsson J, Zurbuchen Y et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. *J Allergy Clin Immunol* 2021;147:545–557.e9. doi:10.1016/j.jaci.2020.10.040.

9. Hanson KE, Caliendo AM, Arias CA et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. *Clin Infect Dis* 2020:ciia1343. doi:10.1093/cid/ciia1343.

10. Lumley SF, O’Donnell D, Stoesser NE et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. *N Engl J Med* 2021;384:533–540. doi:10.1056/NEJMoa2034545.